See more : Ton Yi Industrial Corp. (9907.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Repligen Corporation (RGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Repligen Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Sunonwealth Electric Machine Industry Co., Ltd. (2421.TW) Income Statement Analysis – Financial Results
- M3, Inc. (MTHRF) Income Statement Analysis – Financial Results
- Hibernia REIT Plc (HBRN.L) Income Statement Analysis – Financial Results
- Seojin System Co.,Ltd (178320.KQ) Income Statement Analysis – Financial Results
- Sinqia S.A. (SQIA3.SA) Income Statement Analysis – Financial Results
Repligen Corporation (RGEN)
About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 638.76M | 801.54M | 670.53M | 366.26M | 270.25M | 194.03M | 141.24M | 104.54M | 83.54M | 63.55M | 68.17M | 62.27M | 27.29M | 20.97M | 29.36M | 19.30M | 14.07M | 12.91M | 9.36M | 6.91M | 7.77M | 4.30M | 2.35M | 3.45M | 2.60M | 2.40M | 3.80M | 10.90M | 16.90M | 26.80M | 27.30M | 11.70M | 7.60M | 12.70M | 8.50M | 10.20M | 3.70M | 3.60M |
| Cost of Revenue | 323.54M | 345.83M | 279.28M | 156.63M | 119.10M | 85.95M | 67.05M | 47.12M | 35.25M | 28.02M | 25.16M | 27.17M | 7.12M | 5.51M | 6.78M | 6.16M | 3.61M | 3.55M | 3.89M | 3.25M | 3.48M | 1.99M | 1.12M | 782.23K | 400.00K | 300.00K | 300.00K | 100.00K | -1.10M | 1.50M | -500.00K | -200.00K | -600.00K | 10.50M | 7.60M | 7.20M | 4.40M | 2.60M |
| Gross Profit | 315.23M | 455.71M | 391.25M | 209.63M | 151.15M | 108.08M | 74.19M | 57.42M | 48.29M | 35.53M | 43.01M | 35.10M | 20.17M | 15.46M | 22.58M | 13.14M | 10.46M | 9.36M | 5.47M | 3.67M | 4.29M | 2.31M | 1.22M | 2.67M | 2.20M | 2.10M | 3.50M | 10.80M | 18.00M | 25.30M | 27.80M | 11.90M | 8.20M | 2.20M | 900.00K | 3.00M | -700.00K | 1.00M |
| Gross Profit Ratio | 49.35% | 56.85% | 58.35% | 57.23% | 55.93% | 55.70% | 52.53% | 54.93% | 57.80% | 55.90% | 63.09% | 56.36% | 73.92% | 73.74% | 76.92% | 68.08% | 74.32% | 72.50% | 58.47% | 53.02% | 55.22% | 53.67% | 52.15% | 77.33% | 84.62% | 87.50% | 92.11% | 99.08% | 106.51% | 94.40% | 101.83% | 101.71% | 107.89% | 17.32% | 10.59% | 29.41% | -18.92% | 27.78% |
| Research & Development | 42.72M | 43.94M | 34.27M | 20.18M | 19.45M | 15.77M | 8.67M | 7.36M | 5.74M | 5.61M | 7.34M | 10.49M | 12.53M | 14.16M | 12.77M | 7.24M | 5.92M | 5.16M | 5.04M | 6.48M | 5.23M | 5.36M | 5.79M | 3.75M | 1.80M | 1.40M | 1.40M | 12.30M | 31.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 65.69M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 0.00 | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 631.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 218.11M | 215.83M | 183.87M | 119.62M | 95.61M | 66.32M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 13.23M | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 4.71M | 4.16M | 2.53M | 2.49M | 2.48M | 1.60M | 1.30M | 2.40M | 4.90M | 4.70M | 42.10M | 37.40M | 23.60M | 15.60M | 3.90M | 3.70M | 3.60M | 3.60M | 3.00M |
| Other Expenses | 0.00 | -9.53M | -1.17M | -214.00K | -314.00K | 262.00K | -687.00K | -860.00K | -445.00K | 188.00K | -110.65K | 26.40K | 1.54B | 1.35M | 1.09M | -40.17M | 0.00 | 0.00 | 0.00 | 2.41M | 0.00 | 0.00 | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| Operating Expenses | 261.12M | 259.77M | 218.14M | 139.80M | 115.06M | 82.09M | 60.18M | 38.21M | 30.44M | 22.76M | 20.04M | 23.72M | 20.55M | 21.23M | 18.70M | -22.76M | 12.28M | 10.58M | 9.63M | 13.61M | 9.39M | 7.89M | 8.56M | 6.56M | 3.70M | 2.90M | 4.00M | 18.60M | 38.30M | 44.50M | 39.10M | 24.70M | 16.50M | 4.70M | 4.30M | 4.10M | 4.20M | 3.50M |
| Cost & Expenses | 584.66M | 605.60M | 497.42M | 296.44M | 234.16M | 168.04M | 127.23M | 85.33M | 65.69M | 50.79M | 45.21M | 50.89M | 27.67M | 26.74M | 25.48M | -16.60M | 15.90M | 14.13M | 13.52M | 16.86M | 12.87M | 9.88M | 9.68M | 7.34M | 4.10M | 3.20M | 4.30M | 18.70M | 37.20M | 46.00M | 38.60M | 24.50M | 15.90M | 15.20M | 11.90M | 11.30M | 8.60M | 6.10M |
| Interest Income | 0.00 | 6.98M | 176.00K | 1.74M | 5.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.03M | 1.16M | 12.71M | 12.13M | 9.29M | 6.71M | 6.44M | 3.77M | 32.00K | 49.96K | 49.85K | 56.71K | 26.17K | 1.97K | 2.96K | 2.96K | 0.00 | 696.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 68.56M | 50.99M | 38.45M | 27.07M | 20.87M | 15.78M | 10.45M | 5.33M | 4.59M | 4.02M | 3.11M | 3.51M | 1.67M | 1.38M | 1.08M | 824.63K | 539.03K | 398.43K | 756.26K | 886.71K | 802.23K | 257.54K | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| EBITDA | 127.77M | 246.93M | 211.56M | 101.62M | 58.43M | 41.77M | 24.14M | 24.55M | 22.44M | 15.16M | 26.13M | 14.84M | -30.47K | 1.66M | -3.52M | 6.85M | 36.72M | -1.83M | -1.22M | -2.23M | -8.66M | -4.29M | -5.32M | -7.06M | -4.04M | -2.46M | -615.02K | -2.80M | -6.40M | -17.70M | -16.80M | -9.60M | -11.70M | -7.40M | -1.70M | -2.80M | -600.00K | -4.30M |
| EBITDA Ratio | 20.00% | 23.03% | 25.64% | 19.01% | 13.24% | 13.53% | 9.43% | 17.56% | 20.83% | 20.38% | 33.52% | 18.32% | 4.77% | -20.92% | 16.88% | -28.53% | -15.87% | -15.42% | -48.96% | -101.69% | -62.40% | -149.65% | -388.18% | -105.49% | -7.69% | -25.00% | -10.53% | -25.69% | -37.87% | -62.69% | -35.16% | -100.00% | -132.89% | -14.17% | -32.94% | -21.57% | 310.81% | -86.11% |
| Operating Income | 54.58M | 133.61M | 133.50M | 42.54M | 14.90M | 25.99M | 14.01M | 15.97M | 13.76M | 10.69M | 22.87M | 11.08M | -374.07K | -5.77M | 3.88M | 35.89M | -1.83M | -1.22M | -4.16M | -9.94M | -5.09M | -5.58M | -7.33M | -3.89M | -1.50M | -800.00K | -500.00K | -7.80M | -20.30M | -19.20M | -11.30M | -12.80M | -8.30M | -2.50M | -3.40M | -1.10M | -4.90M | -2.50M |
| Operating Income Ratio | 8.54% | 16.67% | 19.91% | 11.62% | 5.51% | 13.39% | 9.92% | 15.28% | 16.48% | 16.82% | 33.55% | 17.80% | -1.37% | -27.50% | 13.21% | 186.00% | -12.97% | -9.45% | -44.46% | -143.77% | -65.55% | -129.67% | -312.46% | -112.74% | -57.69% | -33.33% | -13.16% | -71.56% | -120.12% | -71.64% | -41.39% | -109.40% | -109.21% | -19.69% | -40.00% | -10.78% | -132.43% | -69.44% |
| Total Other Income/Expenses | 9.56M | -5.53M | -13.71M | -10.61M | -9.93M | -4.55M | -6.76M | -4.28M | -341.00K | 447.58K | 140.82K | -108.34K | -2.35M | 5.72M | 868.07K | 1.89M | 39.76M | 936.07K | 1.92M | 1.18B | 5.40M | 1.12M | 2.05M | 3.52M | 1.86M | 1.96M | 315.02K | 500.00K | 7.80M | 800.00K | 7.90M | 0.00 | 7.10M | 5.90M | 2.50M | 3.70M | 1.10M | 3.50M |
| Income Before Tax | 64.13M | 219.14M | 153.54M | 59.22M | 26.15M | 21.44M | 7.25M | 11.69M | 13.42M | 11.14M | 23.01M | 11.27M | -43.51K | -4.90M | 5.77M | 37.93M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Income Before Tax Ratio | 10.04% | 27.34% | 22.90% | 16.17% | 9.68% | 11.05% | 5.13% | 11.18% | 16.07% | 17.53% | 33.76% | 18.10% | -0.16% | -23.36% | 19.66% | 196.59% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| Income Tax Expense | 22.56M | 33.18M | 25.25M | -709.00K | 4.74M | 4.82M | -21.11M | 11.00K | 4.08M | 2.97M | 6.92M | -2.88M | -330.56K | -834.77K | 26.70K | 827.47K | 889.26K | -696.86K | 2.98M | 9.55M | 4.54M | 4.46M | 5.28M | 3.82M | 2.50M | 800.00K | 500.00K | 11.50M | 32.00M | 19.50M | 11.30M | 12.80M | 5.70M | 2.40M | 3.30M | -300.00K | 20.70M | 1.40M |
| Net Income | 41.58M | 185.96M | 128.29M | 59.93M | 21.41M | 16.62M | 28.35M | 11.68M | 9.35M | 8.17M | 16.09M | 14.16M | -43.51K | -4.06M | 5.75M | 37.11M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Net Income Ratio | 6.51% | 23.20% | 19.13% | 16.36% | 7.92% | 8.56% | 20.07% | 11.17% | 11.19% | 12.86% | 23.61% | 22.73% | -0.16% | -19.38% | 19.57% | 192.30% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| EPS | 0.75 | 3.35 | 2.33 | 1.14 | 0.44 | 0.38 | 0.74 | 0.35 | 0.28 | 0.25 | 0.51 | 0.46 | 0.00 | -0.13 | 0.19 | 1.20 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.75 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| EPS Diluted | 0.74 | 3.24 | 2.24 | 1.11 | 0.44 | 0.37 | 0.72 | 0.34 | 0.28 | 0.25 | 0.50 | 0.45 | 0.00 | -0.13 | 0.18 | 1.18 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.74 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| Weighted Avg Shares Out | 55.72M | 55.46M | 55.02M | 52.55M | 48.34M | 43.77M | 38.23M | 33.57M | 32.88M | 32.50M | 31.67M | 30.91M | 30.78M | 30.75M | 30.96M | 30.83M | 30.38M | 30.13M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.37M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
| Weighted Avg Shares Out (Dil) | 56.38M | 57.46M | 57.26M | 53.89M | 49.21M | 45.47M | 39.15M | 34.10M | 33.58M | 33.26M | 32.41M | 31.25M | 30.78M | 30.75M | 31.29M | 31.32M | 30.38M | 30.69M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.53M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief...
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates
Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago.
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification...
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences.
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics was estimated at US$42.1 Billion in 2023 and is projected to reach US$56.2...
Repligen Opens Training & Innovation Center to Elevate Customer Experience
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters.
Repligen Corporation to Present at Wells Fargo Healthcare Conference
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier...
Source: https://incomestatements.info
Category: Stock Reports